Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Lol, called his bluff
LOL! Well, if you're so confident we're headed to dollar-land any day now, why not just buy my shares for $0.10 right now? Sounds like a steal to me
We will be having a party. Cant wait.
We will be celebrating a much higher pps and you selling all your shares.
Although I will kind of miss having you around.
You know the old story about Ifs and Buts, Candy and Nuts.
If they announce a partnership with a major pharma company you will get your .08 cents.
Looking forward to it.
My apologies. Checked limit and it's set at 08 (not 07), AON
Just confirming. If you have the opportunity to sell your shares at .07, you will?
"We are looking forward to reviewing the final results with our prospective pharmaceutical partner next month."
This right here. We all need to hope and pray this meeting goes very well.
Come on Mr. Chan, Mr. Stern and all the fine folks at Alr Technologies.
If they can put together the kind of deal they have mentioned in previous pr's.....it is going to be huge.
ALR Technologies Announces Successful Preliminary Results
for the GluCurve Pet CGM Non-Inferiority Study
( February 28, 2022 – Singapore) ALR Technologies Inc. (“ALRT” or the “Company”) (OTCQB:
ALRT), the diabetes management company, today announced preliminary results from the NonInferiority Study currently being conducted on the GluCurve Pet CGM (GluCurve).
Utilizing a chemistry analyzer for the baseline, the GluCurve has thus far performed on par with
the leading veterinary Blood Glucose Meter (BGM) and has met all the accuracy requirements
set for human blood glucose meters in ISO: 15197:2013.
“We are pleased with GluCurve’s accuracy as compared to the leading pet BGM used by
veterinarians. The platform has provided valuable diagnostic information throughout the study
that would not be available from traditional in-clinic glucose curve. A significant benefit of
GluCurve is that it is applied in minutes in-clinic and the pet is sent home. GluCurve records
blood sugar levels every 3 minutes for up to 14 days while the pet and owner go about their
daily lives. This presents many benefits compared to BGM whereby 5 to 7 data points are
collected over 8-12 hours in a clinical setting. The process of housing a pet in-clinic and drawing
blood every 2 hours causes stress which elevates their blood glucose levels and is challenging
for the clinic staff to undertake. As part of the study, GluCurve was able to document the
impact on glucose levels from the stressful clinical experience required for BGM testing in real
time,” said Joe Stern, Head of Animal Health at ALR Technologies.
Mr. Stern continues, “The data collected by GluCurve is processed and organized to facilitate
clinicians in providing optimal care with ease. By comparing daily curves, the platform is able to
show clinicians if the pet is receiving insulin injections at the appropriate times, the pet’s eating
habits, and a complete view of the pet’s blood sugar levels over time. Additionally, we have
received feedback from the lead veterinarian in the study confirming what other veterinarians
and animal health companies have told us; they believe the GluCurve Pet CGM will become the
standard of care for the management of diabetic pets. We are looking forward to reviewing the
final results with our prospective pharmaceutical partner next month.
Sorry for the ugly format
Nor do I. Sooner or later, Mr. Chan is going to run out of lifeline to hold onto, and we'll all end up bag holders. I'm going against my better judgment and continue holding. GLTUA
Yeah I don't really blame them
Yeah I don't really blame them
Just a weak hand, think nothing of it.
Wtf what happened, someone got fed up and dumped
0275. Wow. Where are all the ALRT cheerleaders?
It's almost like they were responding to our recent board messages, we have to be the only ones seeing the prs
Great PR. Now at 042 with 8,900 shares traded today. Maybe the next PR can take us to 032! GLTUA. LOL.
This speaks to Mr Chan’ determination to see this through when others would have cashed out. He stayed on task far longer than most people here realize. Looking forward to great success in ‘22 and ‘23.
“A lot goes into the integration of such advanced hardware and software technologies, and our engineering and development team has done a phenomenal job completing the process in preparation for our upcoming non-inferiority study later this month,” says Sidney Chan, Chairman and CEO of ALRT. “This is another major milestone on the path to commercialization this summer which we anticipate will make ALRT cashflow positive in 2022.”
Absolutely, patience will pay off here. The final number that the 50% brings will be very interesting
What sticks out to me is the the partnership info, if they are selling 50% stake that could be worth tens of millions if not hundreds over whatever length of time its structured at. Plus if a major pharmaceutical company is taking over sales and marketing it will grow faster then a new company like ALRT trying to sell it on their own. If they resume talks in march I would think a deal could be finalized and announced as soon as April or maybe May. Either way, the finish lines is quickly approaching
Nothing but good news out of alrt , staying on track to deliver as promised!
NEWS! ALR Technologies Announces Completion of Continuous Glucose Monitor (CGM) Integration and Provides Update on Human Initiatives
February 10, 2022 08:28 ET | Source: ALR Technologies
...
SINGAPORE, Feb. 10, 2022 (GLOBE NEWSWIRE) -- ALR Technologies (“ALRT” or the “Company”) (OTCQB: ALRT), the diabetes management company, today announced the completion of its integration between the GluCurve Pet CGM platform and the Infinovo P3 CGM.
GluCurve Pet CGM is a first of its kind CGM for diabetic cats and dogs that utilizes an adapted version of the ALRT Diabetes Solution platform for Veterinarian Doctors. The GluCurve mobile app collects and displays pet glucose data for the pet owner via Bluetooth from the CGM hardware and securely uploads the data to the cloud where the Company’s technologies analyze and organize the data into a convenient patient management portal for veterinarians. GluCurve offers veterinarians crucial time saving features such as glucose curve comparisons, insulin dose calculators, and information on all the available insulin therapies along with best practice guidelines.
Infinovo’s cutting edge P3 CGM technology is the perfect fit for the GluCurve Pet CGM, utilizing industry leading features such as factory calibration, glucose readings every three minutes, and built-in memory to store up to 14 days of data collected by the CGM.
“A lot goes into the integration of such advanced hardware and software technologies, and our engineering and development team has done a phenomenal job completing the process in preparation for our upcoming non-inferiority study later this month,” says Sidney Chan, Chairman and CEO of ALRT. “This is another major milestone on the path to commercialization this summer which we anticipate will make ALRT cashflow positive in 2022.”
ALRT will be starting the Non-inferiority Study for the GluCurve Pet CGM this month, immediately followed with a Validation Study. With the anticipated successful results of the studies, ALR Technologies will resume talks with global pharmaceutical companies in March with a view to finalize a strategic arrangement thereafter. ALRT plans to sell a 50% stake in GluCurve Pet CGM for working capital in a structured deal which will allow a potential pharmaceutical partner to take control of the sales and marketing activities by utilizing their global presence in animal health and existing relationships with veterinary clinics worldwide for rapid adoption of the GluCurve Pet CGM.
The Company has received various inquiries on the state of the human initiatives in Singapore, Canada, and elsewhere. Having received positive feedback and results on the ALRT Diabetes Solution platform for human health, these initiatives have been put on hold while working towards the commercialization of the GluCurve Pet CGM. The diabetes care industry is calling for the use of CGMs to replace Blood Glucose Meters (“BGM”). The high cost of CGMs is the primary factor holding back patients and payers from replacing BGMs with CGMs. While the ALRT Diabetes Solution is currently bundled with BGMs, the Company is focused on offering the ALRT Diabetes Solution with a cost effective CGM. ALRT is preparing for CGM clinical trial and FDA submission to be completed during 2022. ALR Technologies is targeting to offer the ALRT Diabetes Solution bundled with CGM in 2023 with pricing to compete with the standalone BGM offerings.
About ALR Technologies
ALR Technologies is a data management company that developed the ALRT Diabetes Solution, a comprehensive approach to diabetes care that includes: an FDA-cleared and HIPAA compliant diabetes management system that collects data directly from blood glucose meters and continuous glucose monitoring devices; a patent pending Predictive A1C algorithm to track treatment success between lab reports and an FDA-cleared Insulin Dosing Adjustment program. ALRT also offers an algorithm to provide prescribers support for timely non-insulin medication advancements. The overall goal is to optimize diabetes drug therapies to drive improved patient outcomes. The program tracks performance of all clinical activities to ensure best practices are followed. The ALRT Diabetes Solution gives healthcare providers a platform for remote diabetes care, helping to minimize patient exposure to potential infections in clinical settings. Currently, the Company is focused on diabetes and will expand its services to cover other chronic diseases anchored on verifiable data.
In addition, the animal health division has identified an unmet need in diabetes care and has developed GluCurve; a solution to assist Veterinarian Doctors to determine the efficacy of insulin and to help to identify the appropriate dose and frequency of administration of insulin for companion animals. Thus, delivering the same optimization of diabetic drug therapies to pets as to humans.
On June 1, 2021, ALR Technologies Inc. announced its intention to migrate to Singapore. More information about ALR Technologies Inc. can be found at www.alrt.com. Information regarding ALR Technologies SG Pte. Ltd. can be found at https://sg.alrt.com.
Contact
Ken Robulak (US)
Phone: +1 (727) 736-3838
Anthony Ngai (Singapore)
Phone: +65 3129 2924
Email: ir@alrt.com
CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING INFORMATION:
This news release includes certain “forward-looking statements” as defined under applicable securities legislation. All information and statements contained herein that are not clearly historical in nature constitute forward-looking information, and the words “anticipate”, “estimate”, “believe”, “continue”, “could”, “expect”, “intend”, “plan”, "postulates", "predict", “will”, “may” or similar expressions suggesting future conditions or events or the negative of these terms are generally intended to identify forward-looking information. Forward-looking statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable, are subject to known and unknown risks, uncertainties, and other factors which may cause the actual results and future events to differ materially from those expressed or implied by such forward-looking statements. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Specifically, but not limited to, there is no assurance that the Company will commercialize the GluCurve CGM in 2022, or thereafter, have revenues, earnings, and positive cashflows from the sale of the GluCurve CGM, enter into a strategic agreement with a pharmaceutical for the GluCurve CGM, commence trials for CGM for human health in 2022 or thereafter, apply for FDA clearance to market CGM for human health, or commercialize CGM for human health thereafter. The forward-looking statements included in this news release are made as of the date hereof. ALR Technologies disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.
Sure Buzz. Like I trust the Joe Biden process. LOL
Trust the process.
Rdizz23 - right. BTW, did you see that amazing volume today? 0 shares traded. Maybe ALRT can reverse split this thing 1:21 so we can get to Dollarland!
You'll be lucky if you can get out at .07 in the next 6 months, snooze fest here. Maybe we should poll all of our money and run a tv ad. Helped abwn get some cred. I'll donate $1k. That would be a better investment than paying back the CEOs debt to the company.
Sucker move. I have an AON Sell Order at 07 for 250K shares - frickin' dreamer that I am. Dead money.
So the offering is for .05 and current pps is .047. makes alot of sense, make current shareholders who have been here for years pay a premium. They should be giving us shares, that should be our interest for not tanking the shareprice
There's always hope, always a possibility I guess. I'll hold onto my 250K shares in the very remote possibility that Chan & Co. actually hit on something. But after nearly 5 years waiting, I'm now residing myself to the very likely possibility that I pissed good money down the drain on another sucker penny stock. I mean, what's next for ALRT, a CGM system for insects? GLTUA
Hopefully it's something huge, we thought the Singapore trials was the start of something huge. I could prob form a company today and catch up to them in the market, would probably only take a few months to code an app that reads data from a Bluetooth cgm.
I would be at the same spot as them with no brand recognition beyond penny traders
There were times when my faith was failing. It started for me when they offered a pet medicine reminder. To bring pets into compliance. The pps plummeted from the initial offering. But why jump ship when the value was so low. Simply forgot about it for years. Now look at us, on the verge of something huge.
They should give you a board seat after that long
Oh Four Seven Five - No one here gets out alive!
22+ years and still optimistic. Let’s Go ALRT! Trust the process.
Right, I'm usually an optimist but after 4 years in trying to be a realist now
Mr. "Dollarland" LOS is still pushing the company and his grade-school level insults, I see. All his so-called expertise in diabetes management products and companies have realized us what, a 5¢ stock after how many years of cheer leading?
GLTU.
Signed,
Another $0.047 per share stockholder. LOL
I hear you... I thought things would have taken off years ago myself. I'm just saying its one thing to be frustrated with the company but its another to ignore the present because of the past. They obviously had to pivot because nobody wants to use a new system on BGMs. That makes sense to me. But what you were saying about the pet market was just flat out wrong, not a difference of opinion.
Unless you think the company is committing fraud and lying to shareholders and the SEC I think it is worth digging into what they are doing now instead of just being pissed about the past. The letter to shareholders also said that multiple animal health companies have expressed interest in buying a percentage of the pet cgm and I would assume they would add it to their product list and sell it for ALRT. You don't have to believe that the pet cgm will sell millions of units a year to see that this would still be a deal worth tens of millions if not hundreds depending on your belief in its success.
If they are partnering in the coming month and release a PR with a big name there is no way we will still trade at .05, hopefully you at least agree on that. That would be a chance for people to get out with a big profit, the rest of us will stick around for a few more years and wait for the uplisting they mention in the letter and for the human CGM and all that.
But don't diss the pet cgm just because you haven't researched it. I have done extensive research and if you do have any specific questions i'm happy to answer them
I've been here as long as most and I'm feel stupid for believing that this company was a winner. 4 years later, no word about Singapore, now we are trying to enter a new market because the first entry failed.
I am a software developer, if you give me 6 months I could prob write the same appli cation and work with a doctor on A1c prediction. What they have is nothing proprietary. Chan didn't event the formula to predict A1C
Did you not read the letter to shareholders PR? They are filing for FDA approval this summer after trials for a human CGM. Obviously you are not familiar with diabetes, but the PR explained it very clearly. Their platform works but the industry doesn't want BGMs which is what they were using. They want CGMs.
If you can't follow the logic on the pet market then I will ignore your posts like I do your buddy. Ask a veterinarians, read some studies, look up statistics its all there and very easy to find. there are millions of pets that need a CGM 3 or 4 times a year. The Abbott Libre proves the need, but they will not support animal health. For a veterinarian to use one they have to write a prescription to the pet owner who has to go to a pharmacy and pay full price (cant use insurance) then come back for another appointment with the Vet to put it on. Not to mention there is no software for the Veterinarian to use so they have to just literally look at the pet owners phone. My vet has used one before and he said while medically it is phenomenal to get the data it is not practical so he doesnt use them. He said that a pet CGM sold to veterinarians will literally be the standard of care. if Veterinarians are going to that extreme to use the Libre (which isn't even a CGM its a flash monitor that you have to scan or lose the data every 8 hours) and they dont even make money off it because they dont sell it then its pretty obvious all the information is right about this being a big success. Not to mention ALRT is partnering with an animal health company that obviously also sees the value and further validates the market and need.
They said in the letter to shareholders they are looking to launch the human CGM with their platform the end of next year, so this gives positive cashflow until then.
If you want to hate on the company and stock and plan go right ahead, but at least try to know what you are talking about.
The pet market won't cause the human market to consider us, it makes us a bigger joke. Let's crack the fish market and sell to restaurants to check the blood sugar of the salmon I ordered. Company is grasping at straws
That's what I was kinda getting at, the pet market is almost a cop out, just shifting markets because the human one was impossible to enter with the big boys around.
According to this article, FreeStyle Libre has been available and is a CGM, lasting up to 14 days before sensor replacement, and has been available since 2019. Even though, according to the article, Abbott doesn't support for pet use. But, it is being used.
Almost 5 years now. We went from huge hope in human application, to now pets. I'd sell my measley 1/4 million shares for 07 right now if someone would buy them. That way I could double my money and the buyer can hang on for dollarland.
FreeStyle Libre
You are looking at BGMs, that has nothing to do with CGMs
I found about 5 more that are out on the market directed for pet owners between $30-50.
So alrt is pretty late to every game. I've been here almost 5 years now. We clearly don't have the game changer we thought 4 years ago after the FDA approval
Just did a quick Google search and there already is a pet gcm on the market
https://www.chewy.com/alphatrak-2-blood-glucose-monitoring/dp/262434?utm_source=google-product&utm_medium=cpc&utm_campaign=hg&utm_content=AlphaTRAK&utm_term=&gclid=CjwKCAiA0KmPBhBqEiwAJqKK45VE59kxGKF6oavwpuZB3H3oCfbT-ZAlH1QWA8ZA8WdyIO8w1ihk8xoCWNMQAvD_BwE
Followers
|
148
|
Posters
|
|
Posts (Today)
|
2
|
Posts (Total)
|
13372
|
Created
|
10/05/09
|
Type
|
Free
|
Moderators |
|
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |